The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis

Advances in Therapy

Volumn 25, Issue 3, 2008, Pages 190-200

  Kilic, Z Mesut Yalin ^a,b   Kuran, Sedef ^a   Akdogan, Meral ^a   Cicek, Bahattin ^a   Oguz, Dilek ^a   Odemis, Bulent ^a   Sasmaz, Nurgul ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Hepatitis B; Lamivudine; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; AMYLASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; CREATININE; DIURETIC AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PROTEIN; UREA; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CHEMOEMBOLIZATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; ECHOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; HEMOSTASIS; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SURVIVAL; UREA BLOOD LEVEL; VIRUS REPLICATION;

EID: 59249088872     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0038-6     Document Type: Article

References (30)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
2. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103:1630-1635.
3. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1994;21:656-666.
4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology. 1991;13:627-631.
5. Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: For whom and when? J Hepatol. 2000;33:329-332.
6. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology. 2001;34:411-416.
7. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000;33:308-312.
8. Bolukbas C, Bolukbas FF, Kendir T, et al. The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: A prospective, open-label study. Dig Dis Sci. 2006;51:1196-1202.
9. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-2895.
10. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908-916.
11. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
12. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology. 1997;113:1258-1263.
13. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut. 2000;46:562-568.
14. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology. 2003;124:105-117.
15. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207-210.
16. Perrillo RP, Wright T, Rakela J, et al. Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33:424-432.
17. Andreone P, Biselli M, Gramenzi A, et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation. 2002;74:1119-1124.
18. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57-63.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
20. Karayalçin S, Yurdaydin C, Bozdayi AM, Bozkaya H. Is it possible to decrease at one year the lamivudine treatment induced serum HBV-DNA breakthrough rates? Gastroenterology. 2000;118(suppl):2348. Abstract.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
23. Lok AS, McMahon BJ. Corrections to AASLD guidelines on chronic hepatitis B. Hepatology. 2007;45:1347.
24. Fontana RJ, Keeffe EB, Carey W, et al. Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433-439.
25. Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-Hbe positive/HBeAg-negative chronic hepatitis B. Clin Transplant. 2005;19:321-326.
26. Ooga H, Suzuki F, Tsubota A, et al. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2004;39:1078-1084.
27. Hann HW, Fontana RJ, Wright T, et al. United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003;9:49-56.
28. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat. 2005;12:398-404.
29. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15(suppl E):25-30.
30. Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34:569-572.